The £6 million from AMR Action Fund will support the completion of Phase I clinical studies for CTX-187, Centauri’s lead clinical candidate in the ABX-01 programme.
Cheshire-based immunotherapy company Centauri Therapeutics has extended its Series A round of funding to £30 million. This is thanks to £6 million from AMR Action Fund, the world’s largest venture capital fund dedicated to investing in antimicrobial therapeutics.
The investment will support the completion of Phase I clinical studies for CTX-187, Centauri’s lead clinical candidate in the ABX-01 programme and will expand the scope of additional research activities in preparation for Phase II.
Built on the company’s platform, CTX-187 is a broad-spectrum antimicrobial designed to treat clinically prevalent and multidrug-resistant Gram-negative bacteria, expanding therapeutic options for vulnerable patients. It features a dual mechanism-of-action that combines immunotherapeutic effects through complement activation and opsonophagocytosis with intrinsic antibacterial activity.
“The growing burden of drug-resistant Gram-negative infections is one of the most pressing challenges in global health, leaving patients with limited and increasingly ineffective treatment options,” said AMR Action Fund’s chief executive Henry Skinner.
“Centauri’s approach represents a promising opportunity to address this challenge,” he continued.
Centauri originally closed its £24 million Series A round in January 2022, with investment from Boehringer Ingelheim Venture Fund, Evotec SE and Novo Holdings REPAIR Impact Fund.
